![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Chomitz0324_JCP8700s-scaled.jpg)
An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Join this webinar to learn how a new single medium, Rapid Sterility Medium (RSM), performs as well as or better for the growth promotion of test microorganisms compared to compendial sterility test media.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2435601203.jpg)
First-in-class combination therapy authorised for endometriosis
The three-in-one oral daily tablet provides an additional treatment option to help women in the UK manage their endometriosis-associated pain.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_576965746.jpg)
Advancing NOX inhibitors for treating fibrotic diseases and cancer
This article explores the benefit of NOX inhibitors for fibrotic diseases and cancers and highlights the potential of Calliditas’ setanaxib.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Chomitz0324_JCP8700s-scaled.jpg)
New webinar: Simplify your move from a vial to a prefilled syringe
Join this webinar to learn how a new single medium, Rapid Sterility Medium (RSM), performs as well as or better for the growth promotion of test microorganisms compared to compendial sterility test media.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1543267175-1.jpg)
New WHO guidance to support manufacturers to reduce AMR risk
The recommendations offered in the guidance applies across different phases of manufacturing, from APIs, through to formulation and packaging.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2394865731.jpg)
Improving upstream fermentation with end-to-end automation
The automated system “significantly improved process control”, resulting in greater productivity of a small-molecule drug substance.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2499211713.jpg)
Innovative hypertension polypill study achieves “significant” outcomes
The triple pill demonstrated “impressive” blood pressure control for the participants compared to standard of care.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2270276669.jpg)
Sustainable PFAS-free synthesis for pharmaceutical compounds
The novel, environmentally-friendly synthesis strategy holds potential for manufacturing scale up, according to the research.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2196912265.jpg)
Mpox update – August 2024
This article discusses the impact of the recent mpox emergency, highlighting the industry’s response and potential vaccine candidates.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1652254300.jpg)
Novartis collaboration to innovate subcutaneous drug delivery
The multi-target agreement could enhance treatment convenience by improving subcutaneous administration options for patients.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1931085251.jpg)
Innovative pharma-government partnership to enhance UK clinical trials
The innovative programme supports the UK government’s objectives to boost clinical trials and increase competitiveness in life sciences.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/astrazeneca-1.jpg)
AstraZeneca investment to increase biologic capacity in Sweden
The planned expansion is set to strengthen AstraZeneca’s capability to manufacture biologic medicines for patients globally.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_1216682005.jpg)
European Commission licenses first treatment for acanthamoeba keratitis
Following its European approval, the small molecule treatment is set to become the standard of care for patients with the ultra-rare disease.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2245939183.jpg)
Semi-automatic method could provide “superior” bacterial characterisation analysis
The analysis technique offers “significant” advantages over traditional colony forming unit (CFU) counts, according to the paper.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2475238459.jpg)
Alzheimer’s drug milestone “bittersweet” for certain patients
The first new dementia therapy to be licensed in over 20 years, has for the first time, shown efficiency in delaying cognitive decline.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/West-Pharma-asset-1.jpg)
Are we set for the revised EU GMP Annex 1?
This blog is a summary of the key changes of relevance to primary packaging components
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2393526337-1.jpg)
Innovative mass spec method may improve oligonucleotide therapeutic analysis
The nonIP-RP-LC-MS method provides an “easy, reliable, and cost-effective” approach for bioanalysing oligonucleotide therapies.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2476496947.jpg)
Harnessing the GLP-1R medicine wave
As a promising treatment for T2D and obesity, based on key trial data, the GLP-1R therapy market looks set to produce major sales up to 2030.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2178527227.jpg)
First-of-a-kind trial holds promise for obesity and pre-diabetes treatment
The treatment may reduce the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or who are overweight.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2163350433.jpg)
Enhancing cell proliferation in bioproduction with non-invasive technology
The method has potential in both biomanufacturing and production of autologous cell therapies, the research suggests.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2236452859.jpg)
Genmab appoints new EVP and Chief Technology Officer
The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2447804783.jpg)
Targeted therapies for chronic lymphocytic leukaemia in an evolving treatment landscape
Chief Medical Officer for Hematology, BeiGene, discusses the evolution of therapies for CLL and the promise of targeted treatments.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2182973299.jpg)
First-in-class therapy approved for chronic skin disease
The biologic targets a key driver of prurigo nodularis, with trial data demonstrating improved itch as well as skin nodules for patients.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_2168454889.jpg)
Sustainable QC method for antimicrobial quantification
The new fluorimetric approach could help to mitigate clinical demand for the treatment of multidrug-resistant bacterial infections.
![](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/shutterstock_158258786.jpg)
Innovative vaccine demonstrates sustained malaria immunisation in pregnancy
Follow up research to the presented findings could provide improved opportunities for preventing malaria in women during pregnancy.